J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer
TL;DR: Patients with relapsed ovarian cancer can now survive several years; the aim is to increase this further.
Journal ArticleDOI
Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
TL;DR: The body of evidence currently available supports the recommendation that i.
Journal ArticleDOI
Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
Jonathan A. Ledermann,Ronnie Shapira-Frommer,Alessandro D. Santin,Alla Lisyanskaya,Sandro Pignata,Ignace Vergote,F. Raspagliesi,Gabe S. Sonke,Michael J. Birrer,Diane Provencher,Jalid Sehouli,Nicoletta Colombo,Antonio González-Martín,Ana Oaknin,Petronella B. Ottevanger,Vilius Rudaitis,Razvan Cristescu,J. Kobie,Jane Ruman,Ursula A. Matulonis +19 more
Journal ArticleDOI
A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.
J. D. Howell,Colin S. McArdle,David J. Kerr,J. Buckles,Jonathan A. Ledermann,Irving Taylor,H. J. Gallagher,J. Budden +7 more
TL;DR: The response rate of this regimen compares favourably with reported trials of intra-arterial FUDR, and the schedule is currently being compared with a similar schedule of intravenous 5-FU and folinic acid in a randomized Medical Research Council trial (CR05).
Journal ArticleDOI
Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation
Jonathan A. Ledermann,A.J. Dembo,Jeremy Sturgeon,S. Fine,R.S. Bush,Anthony Fyles,J.F. Pringle,G.A. Rawlings,Gillian Thomas,J. Simm +9 more
TL;DR: Chemotherapy followed by abdominopelvic radiotherapy seems a reasonable management policy in patients with Stage II or III ovarian cancer who have tumor with unfavorable histopathological characteristics and/or small residual disease, who could be improved by giving chemotherapy before radiation.